<DOC>
	<DOCNO>NCT00720577</DOCNO>
	<brief_summary>Part A . The purpose study assess effect 6 week treatment , simvastatin , losartan pioglitazone compare placebo RNA expression profile low extremity peripheral arterial atherosclerotic plaque . Part B . The effect simvastatin , losartan pioglitazone compare placebo protein lipid biomarkers low extremity peripheral arterial atherosclerotic plaque .</brief_summary>
	<brief_title>Study Evaluate Effect Simvastatin , Losartan Pioglitazone Patients With Peripheral Arterial Disease .</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled , 6 week study . The study consist 3 separate sub-studies patient undergo bilateral low extremity peripheral artery atherectomy receive one three FDA approve drug know beneficial effect risk cardiovascular disease . Patients select particular sub-study base series entry criterion randomize particular agent placebo 6-weeks .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Plaque , Atherosclerotic</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Men woman =90 year age . Bilateral low extremity PAD require revascularization . Both extremity must least 1denovo atherosclerotic lesion Able space bilateral atherectomy procedure least 6 week . Willing provide inform consent participation genetic study . Simvastatin Substudy LDLC &gt; 100 mg/dL &lt; 250 mg/dL TG &lt; 350 mg/dL Not currently receive take statin ( simvastatin , lovastatin , rosuvastatin , atorvastatin , pravastatin ) combination product contain statin previous 3 month . Losartan Substudy Diagnosis hypertension systolic blood pressure &gt; 120 mm Hg &lt; 160 mm Hg , diastolic blood pressure &gt; 80 mm Hg &lt; 100 mm Hg . Not currently receive take ACEi ARB . Pioglitazone Substudy Type II diabetes mellitus HbA1c &gt; 5.5 % &lt; 8.5 % Otherwise stable glucose lower regimen change expect oral regimen , change insulin dose 10 U expect . Not currently receive take thiazolidinedione ( rosiglitazone pioglitazone ) combination product contain thiazolidinedione previous 12 month . Patient pregnant , breastfeeding , expect conceive study include 14day post study followup . current condition , therapy , lab abnormality , mental legal incapacitation investigator 's judgment might confound result study . Patient currently participate participate study investigational compound within 30 day Visit 1 . Patient donate and/or receive blood ( include phlebotomy &gt; 300 mL ) within 2 month prior study . Surgery significant trauma within 2 month prior Visit 1 . Patient user recreational illicit drug recent history &lt; 1yr drug/alcohol abuse &gt; 2 alcoholic drink per day ) . Patient &lt; 80 % compliant dosing placebo runin period AND , opinion investigator , believe unable maintain least 80 % compliance dose active study dose period . Patient history myocardial infarction , stroke , coronary artery bypass surgery coronary , carotid , cerebral revascularization procedure , unstable angina , angioplasty within 1 month Visit 1 . Patient chronic heart failure define New York Heart Association NYHA ) Classes III IV . Known clinically significant AV conduction disturbance arrhythmias Patient unstable hypertension ( e.g. , sit systolic blood pressure &gt; 160 mm Hg diastolic &gt; 100 mm Hg ) Visit 1 . Any know clinically important bleed platelet disorder . Patient history ileal bypass , gastric bypass , significant condition associate malabsorption . Patient HIV hepatitis B positive . Patients significantly elevate TSH Visit 1 may enter consultation approval SPONSOR . Patients history hypothyroidism , stable dose thyroxine normal TSH level Visit 1 may include . Patients cyclical estrogen medication ( Estrogen Replacement Therapy ERT ] oral contraceptive ) . Patients noncyclical estrogen replacement therapy Selective Estrogen Receptor Modulator ( SERM ) may include , must stable dose least 8 week prior . Patients active neoplastic disease compromise general health , currently require chemotherapy radiation therapy , complete chemotherapy radiation therapy within 3 month prior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>PAD</keyword>
	<keyword>Lower extremity peripheral arterial atherosclerotic plaque</keyword>
	<keyword>RNA Expression</keyword>
	<keyword>Lipid Biomarkers</keyword>
</DOC>